Please login to the form below
Oxervate
This page shows the latest Oxervate news and features for those working in and with pharma, biotech and healthcare.
European Commission approves Dompé’s orphan drug
Oxervate will treat patients with neurotrophic keratitis. Italian biopharmaceutical company Dompé has received the go-ahead for Oxervate (cenegermin) for the treatment of moderate-to-severe neurotrophic keratitis (NK), a rare ... Aringhieri added:
Latest news
-
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog
Dompé Farmaceutici's Oxervate (cenegermin) was recommended for the treatment of moderate to severe neurotrophic keratitis, and there was also a positive opinion for an advanced therapy medical product (ATMP) - Co
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Twist Health
Not just another healthcare communications agency. We are a collection of award-winning industry experts focusing on bringing the very best...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
